Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company May 22, including a shift in R&D focus and restructuring of Japan operations. The pharma anticipates a decline in its FY19 core operating profit due to loss of exclusivity for key products and aims to generate mid- to

Read the full 613 word article

User Sign In